乳腺癌可根据雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2)的表达情况分为4种分子亚型:①管腔A型(ER+、PR+、HER2-),②管腔B型(ER+、PR+、HER2+),③三阴型(ER-、PR-、HER2-),④HER2过表达型(ER-、PR-、HER2+)。其中ER阳性乳腺癌约占所有乳腺癌的70%。尽管大多数患者在最初诊断时尚处...
New Treatment Options in ER-Positive, HER2-Positive and Triple-Negative Breast CancerDiagnostic criteriaPathologyWHO classificationBreast CancerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, ...
(PR) and human epidermal growth factor receptor 2 (HER2) inhibited USP15-mediated PARP1 stabilization through different mechanisms. ER bound to theUSP15promoter to suppress its expression, PR suppressed the deubiquitinase activity of USP15, and HER2 abrogated the PARP1–USP15 interaction. The ...
CASE REPORT:A 41-year-old woman presented with a right breast mass that had been growing for 2 months. Biopsy confirmed breast SCC, a rare malignancy with IHC profile as follows: HER2 overexpression, ER positive, and PR negative. She underwent neoadjuvant chemotherapy for 3 months followed by ...
Table. ER-Targeting Therapies in Development for ER-positive, HER2-negative Breast Cancer Standard of Care Nearly 80% of breast cancers express the ER, making it the most significant driver of this tumor type. In patients with ER-positive breast cancer, endocrine therapy has been the gold stand...
A recruitment of 20 women with oestrogen receptor (ER) positive breast cancer (who are already on standard of care hormone therapy who are being treated with curative intent) is aimed for; which means that the disease has not yet spread to distant parts of the body. Each subject will be ...
Endocrine resistance poses a significant clinical challenge for patients with hormone receptor-positive and human epithelial growth factor receptor 2-negative (HR + HER2−) breast cancer. Dysregulation of estrogen receptor (ER) and ERBB signaling
MAF amplification increases the risk of breast cancer (BCa) metastasis through mechanisms that are still poorly understood yet have important clinical implications. Oestrogen-receptor-positive (ER+) BCa requires oestrogen for both growth and metastasis,
Indication: ORSERDU (elacestrant), 345 mg tablets, is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression ...
Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor (ER) positive/human growth epidermal growth factor 2 (HER2) negative (ER+/HER2-) locally advanced ...